A Phase 2 interventional study of 180mg of ETC-1002(bempedoic acid) and 120mg of ETC-1002(bempedoic acid) in Hypercholesterolemia, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2024-05-10.
Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing bempedoic acid in Hypercholesterolemia — 1 open to participants now, 1 under way, 1 of them phase 3. bempedoic acid · Hypercholesterolemia.
Among the 21 studies testing bempedoic acid in Hypercholesterolemia, this one is the 8th largest by enrollment, is the only one that started in 2021, is one of 10 in phase 2, and was the 15th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 21 studies testing bempedoic acid in Hypercholesterolemia is open now, in 3 countries. Recruiting first, the newest first:
Daiichi Sankyo · Sites in Germany, Italy, Spain
Ages 18+
By country, each count listing its studies:
bempedoic acid: first FDA approval 2020 (NEXLETOL), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 20 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 188 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 126 across the 21 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 21 have an industry lead sponsor. The 6 most frequent:
This study is registered under Otsuka Pharmaceutical Co., Ltd., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 143 studies on the registry; 11 are open to participants now.
Otsuka Holdings Co., Ltd. has 2 studies filed under Hypercholesterolemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing bempedoic acid in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the low-density lipoprotein cholesterol (LDL-C)-lowering efficacy and safety of ETC-1002(bempedoic acid) 60 mg, 120 mg and 180 mg versus placebo added to ongoing stable statin therapy or other lipid-modifying therapies in Japanese patients with hypercholesterolemia treated for 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with a history or current symptoms of any of the following cardiovascular diseases within 3 months prior to screening or before baseline visit
Uncontrolled hypertension, defined as follows:
Patients with liver disease or dysfunction, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: 180mg of ETC-1002(bempedoic acid)
Drug: 120mg of ETC-1002(bempedoic acid)
Drug: 60mg of ETC-1002(bempedoic acid)
Drug: Placebo
180mg, tablet, once daily, for 12 weeks
120mg, tablet, once daily, for 12 weeks
60mg, tablet, once daily, for 12 weeks
placebo, tablet, once daily, for 12 weeks
Percent Change in LDL-C From Baseline to Week 12
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Day 1. When LDL-C at Week 12 was missing, the missing value was imputed using the last observation carried forward from the start of the IMP administration to 2 days after the final IMP administration.
Time frame: Baseline, week12
Percent Change in HDL Cholesterol From Baseline to Week 12
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
Time frame: Baseline, week12
Percent Change in Non-HDL Cholesterol From Baseline to Week 12
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
Time frame: Baseline, week12
Percent Change in Total Cholesterol From Baseline to Week 12
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
Time frame: Baseline, week12
Percent Change in Triglycerides From Baseline to Week 12
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
Time frame: Baseline, week12
Percent Change in Apolipoprotein B From Baseline to Week 12
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
Time frame: Baseline, week12
Percent Change in High Sensitivity C Reactive Protein From Baseline to Week 12
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
Time frame: Baseline, week12
Percent Change in Hemoglobin A1c From Baseline to Week 12
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
Time frame: Baseline, week12
Proportion of Subjects Whose LDL-C Value Achieved the Lipid Management Goals Based on Risk Assessment at Week 12
The proportion of subjects whose LDL-C value achieves the lipid management goal at Week 12.
Time frame: Baseline, week12
Proportion of Subjects Whose LDL-C Value Achieve < 70 mg/dL at Week 12
The proportion of subjects whose LDL-C value achieves \<70 mg/dL at Week 12.
Time frame: Baseline, week12
| Milestone | ETC-1002 60 mg | ETC-1002 120 mg | ETC-1002 180 mg | Placebo |
|---|---|---|---|---|
| Started | 47 | 46 | 48 | 47 |
| Completed | 44 | 46 | 46 | 46 |
| Not completed | 3 | 0 | 2 | 1 |
| Withdrew: Adverse event | 1 | 0 | 2 | 1 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 1 | 0 | 0 | 0 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100. Baseline was defined as the mean of the values from Week -1 and Day 1. When LDL-C at Week 12 was missing, the missing value was imputed using the last observation carried forward from the start of the IMP administration to 2 days after the final IMP administration.
| Percent Change | ETC-1002 60 mg | ETC-1002 120 mg | ETC-1002 180 mg | Placebo |
|---|---|---|---|---|
| Percent Change in LDL-C From Baseline to Week 12 | -10.59 ± 2.153 | -21.85 ± 2.156 | -21.26 ± 2.095 | -1.92 ± 2.117 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
| Percent Change | ETC-1002 60 mg | ETC-1002 120 mg | ETC-1002 180 mg | Placebo |
|---|---|---|---|---|
| Percent Change in HDL Cholesterol From Baseline to Week 12 | 0.16 ± 2.208 | -0.65 ± 2.190 | -7.29 ± 2.139 | 3.08 ± 2.155 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
| Percent Change | ETC-1002 60 mg | ETC-1002 120 mg | ETC-1002 180 mg | Placebo |
|---|---|---|---|---|
| Percent Change in Non-HDL Cholesterol From Baseline to Week 12 | -8.86 ± 2.019 | -18.29 ± 2.021 | -16.01 ± 1.956 | -1.62 ± 1.988 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
| Percent Change | ETC-1002 60 mg | ETC-1002 120 mg | ETC-1002 180 mg | Placebo |
|---|---|---|---|---|
| Percent Change in Total Cholesterol From Baseline to Week 12 | -6.42 ± 1.665 | -13.61 ± 1.650 | -13.56 ± 1.599 | -0.55 ± 1.621 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
| Percent Change | ETC-1002 60 mg | ETC-1002 120 mg | ETC-1002 180 mg | Placebo |
|---|---|---|---|---|
| Percent Change in Triglycerides From Baseline to Week 12 | -9.09 ± 6.286 | -5.62 ± 6.290 | 9.17 ± 6.151 | -0.08 ± 6.219 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
| Percent Change | ETC-1002 60 mg | ETC-1002 120 mg | ETC-1002 180 mg | Placebo |
|---|---|---|---|---|
| Percent Change in Apolipoprotein B From Baseline to Week 12 | -8.18 ± 1.715 | -14.59 ± 1.709 | -12.47 ± 1.704 | -2.13 ± 1.704 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
| Percent Change | ETC-1002 60 mg | ETC-1002 120 mg | ETC-1002 180 mg | Placebo |
|---|---|---|---|---|
| Percent Change in High Sensitivity C Reactive Protein From Baseline to Week 12 | 150.54 ± 62.494 | 1.02 ± 62.418 | -34.58 ± 62.745 | 0.98 ± 61.513 |
Percent change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] divided by the Baseline value) x 100.
| Percent Change | ETC-1002 60 mg | ETC-1002 120 mg | ETC-1002 180 mg | Placebo |
|---|---|---|---|---|
| Percent Change in Hemoglobin A1c From Baseline to Week 12 | 0.11 ± 0.591 | -0.40 ± 0.596 | -0.21 ± 0.592 | -0.05 ± 0.578 |
The proportion of subjects whose LDL-C value achieves the lipid management goal at Week 12.
| participants | ETC-1002 60 mg | ETC-1002 120 mg | ETC-1002 180 mg | Placebo |
|---|---|---|---|---|
| Proportion of Subjects Whose LDL-C Value Achieved the Lipid Management Goals Based on Risk Assessment at Week 12 | 15 | 26 | 28 | 1 |
The proportion of subjects whose LDL-C value achieves \<70 mg/dL at Week 12.
| Participants | ETC-1002 60 mg | ETC-1002 120 mg | ETC-1002 180 mg | Placebo |
|---|---|---|---|---|
| Proportion of Subjects Whose LDL-C Value Achieve < 70 mg/dL at Week 12 | 0 | 1 | 0 | 0 |
Collected over Adverse events were monitored from signing of the informed consent form until follow-up for up to 28 (+7) days after the last dose of study medication.. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ETC-1002 60 mg | 0/47 (0%) | 0/47 (0%) | 23/47 (48.9%) |
| ETC-1002 120 mg | 0/46 (0%) | 0/46 (0%) | 17/46 (37%) |
| ETC-1002 180 mg | 0/47 (0%) | 1/47 (2.1%) | 21/48 (43.8%) |
| Placebo | 0/48 (0%) | 1/48 (2.1%) | 9/47 (19.1%) |
| Event | ETC-1002 60 mg | ETC-1002 120 mg | ETC-1002 180 mg | Placebo |
|---|---|---|---|---|
| Calculus urinaryRenal and urinary disorders | 0/47 | 0/46 | 1/47 | 0/48 |
| Dental cystGastrointestinal disorders | 0/47 | 0/46 | 0/47 | 1/48 |
| Event | ETC-1002 60 mg | ETC-1002 120 mg | ETC-1002 180 mg | Placebo |
|---|---|---|---|---|
| HeadacheNervous system disorders | 0/47 | 5/46 | 2/48 | 0/47 |
| PyrexiaGeneral disorders | 5/47 | 4/46 | 1/48 | 2/47 |
| Hepatic function abnormalHepatobiliary disorders | 2/47 | 0/46 | 5/48 | 0/47 |
| Abdominal pain upperGastrointestinal disorders | 4/47 | 1/46 | 0/48 | 0/47 |
| MalaiseGeneral disorders | 1/47 | 3/46 | 3/48 | 0/47 |
| Vaccination site painGeneral disorders | 1/47 | 3/46 | 0/48 | 1/47 |
| Blood uric acid increasedInvestigations | 2/47 | 3/46 | 1/48 | 0/47 |
| DiarrhoeaGastrointestinal disorders | 3/47 | 1/46 | 1/48 | 1/47 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/47 | 2/46 | 2/48 | 0/47 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/47 | 1/46 | 3/48 | 3/47 |
For the full analysis set (FAS), a total of 186 subjects (45 for the 60 mg group, 46 for the 120 mg group, and 48 for the 180 mg group were included in the ETC-1002 group, and 47 subjects were included in the placebo group).
| Age, Categorical(Participants) | ETC-1002 60 mg | ETC-1002 120 mg | ETC-1002 180 mg | Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 28 | 27 | 23 | 20 | 98 |
| >=65 years | 17 | 19 | 25 | 27 | 88 |
| Age, Continuous(years) | ETC-1002 60 mg | ETC-1002 120 mg | ETC-1002 180 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 60.9 ± 9.26 | 60.4 ± 8.94 | 60.4 ± 11.98 | 63.0 ± 10.65 | 61.2 ± 10.28 |
| Sex: Female, Male(Participants) | ETC-1002 60 mg | ETC-1002 120 mg | ETC-1002 180 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 16 | 16 | 16 | 12 | 60 |
| Male | 29 | 30 | 32 | 35 | 126 |
| Race/Ethnicity, Customized(Participants) | ETC-1002 60 mg | ETC-1002 120 mg | ETC-1002 180 mg | Placebo | Total |
|---|---|---|---|---|---|
| Asian | 45 | 46 | 48 | 47 | 186 |
| Region of Enrollment(participants) | ETC-1002 60 mg | ETC-1002 120 mg | ETC-1002 180 mg | Placebo | Total |
|---|---|---|---|---|---|
| Japan | 45 | 46 | 48 | 47 | 186 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — : Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.
Ran from Mar 2021 to primary completion in Apr 2022, 12 months.
Results were first posted in Mar 2024, 1 year 10 months after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 12 months is above that.
Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bempedoic acid
Otsuka Pharmaceutical Co., Ltd. →